title: Challenges to Biomarker Testing for PD-1/PD-L1 Checkpoint Inhibitors for Lung Cancer.
authors.forename: Philip T
authors.initials: PT
authors.lastname: Cagle
authors.affiliation: From the Department of Pathology and Genomic Medicine (Dr. Cagle) and Houston Methodist Cancer Center (Dr. Bernicker), Houston Methodist Hospital, Houston, Texas.
authors.forename: Eric H
authors.initials: EH
authors.lastname: Bernicker
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D060890:B7-H1 Antigen / Q000032:analysis* / Q000037:antagonists & inhibitors; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000037:antagonists & inhibitors; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000276:immunology; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000032:analysis* / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D060890:B7-H1 Antigen; D014408:Biomarkers, Tumor; C423236:CD274 protein, human; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab; C582435:pembrolizumab